Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro

Haemophilus influenzae is a common bacterial pathogen causing human respiratory tract infections. We have previously shown that the beta2-agonist salmeterol reduces damage to the respiratory mucosa caused by Pseudomonas aeruginosa in vitro. We have now investigated the effect of salmeterol on H. influenzae infection of adenoid tissue in an organ culture by scanning electron microscopy. Tissue was preincubated with or without salmeterol (4x10(-7)M), prior to infection with H. influenzae and incubated for 12 or 24 h. Infected organ cultures had increased epithelial damage and decreased numbers of both ciliated and unciliated cells at 12h, which were significantly different (p < or = 0.01) from the controls at 24 h. Salmeterol (4x10(-7)M) significantly (p < or = 0.03) reduced damage and loss of ciliated cells in infected organ cultures at both 12 and 24, and significantly (p < or = 0.03) reduced loss of unciliated cells at 24 h. Salmeterol had no effect on the density of bacteria adhering to each individual mucosal feature or the total number of bacteria adhering to the organ culture. These results suggest that salmeterol protects the respiratory epithelium against Haemophilus influenzae-induced damage. The mechanism of salmeterol cytoprotection and its potential clinical relevance remain to be investigated.

This article has been cited by other articles:

				G D Perkins, F Gao, and D R Thickett In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury Thorax, March 1, 2008; 63(3): 215 - 220. [Abstract] [Full Text] [PDF]

				P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]

				C. Coraux, C. Kileztky, M. Polette, J. Hinnrasky, J.-M. Zahm, P. Devillier, S. de Bentzmann, and E. Puchelle Airway Epithelial Integrity Is Protected by a Long-Acting {beta}2-Adrenergic Receptor Agonist Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 605 - 612. [Abstract] [Full Text] [PDF]

				D. P. Tashkin and C. B. Cooper The Role of Long-Acting Bronchodilators in the Management of Stable COPD Chest, January 1, 2004; 125(1): 249 - 259. [Abstract] [Full Text] [PDF]

				J. A Dougherty, B. L Didur, and L. S Aboussouan Long-Acting Inhaled {beta}2-Agonists for Stable COPD Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255. [Abstract] [Full Text] [PDF]

				M. Johnson and S. Rennard Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD Chest, July 1, 2001; 120(1): 258 - 270. [Abstract] [Full Text] [PDF]

				R. L. ZuWallack, D. A. Mahler, D. Reilly, N. Church, A. Emmett, K. Rickard, and K. Knobil Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD Chest, June 1, 2001; 119(6): 1661 - 1670. [Abstract] [Full Text] [PDF]

				P. J. Barnes Chronic Obstructive Pulmonary Disease N. Engl. J. Med., July 27, 2000; 343(4): 269 - 280. [Full Text] [PDF]

				G. P. ANDERSON Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S188 - 196. [Full Text] [PDF]